ES2562789T3 - Supresión de la amplificación usando un oligonucleótido y una polimerasa que carece significativamente de actividad exonucleasa 5'-3' - Google Patents
Supresión de la amplificación usando un oligonucleótido y una polimerasa que carece significativamente de actividad exonucleasa 5'-3' Download PDFInfo
- Publication number
- ES2562789T3 ES2562789T3 ES08785392.5T ES08785392T ES2562789T3 ES 2562789 T3 ES2562789 T3 ES 2562789T3 ES 08785392 T ES08785392 T ES 08785392T ES 2562789 T3 ES2562789 T3 ES 2562789T3
- Authority
- ES
- Spain
- Prior art keywords
- sequence
- blocking oligonucleotide
- oligonucleotide
- target
- target sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 189
- 230000003321 amplification Effects 0.000 title claims abstract description 74
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 74
- 230000000694 effects Effects 0.000 title claims abstract description 57
- 108060002716 Exonuclease Proteins 0.000 title claims abstract description 37
- 102000013165 exonuclease Human genes 0.000 title claims abstract description 37
- 230000001629 suppression Effects 0.000 title description 6
- 230000000903 blocking effect Effects 0.000 claims abstract description 153
- 239000002773 nucleotide Substances 0.000 claims abstract description 87
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 87
- 239000000523 sample Substances 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 55
- 238000006243 chemical reaction Methods 0.000 claims abstract description 40
- 230000000295 complement effect Effects 0.000 claims abstract description 32
- 238000009396 hybridization Methods 0.000 claims abstract description 29
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 29
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 29
- 239000002157 polynucleotide Substances 0.000 claims abstract description 29
- 101710163270 Nuclease Proteins 0.000 claims abstract description 10
- 238000009830 intercalation Methods 0.000 claims abstract description 9
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 9
- 239000012472 biological sample Substances 0.000 claims abstract description 8
- 230000001419 dependent effect Effects 0.000 claims abstract description 4
- 230000004927 fusion Effects 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 238000002844 melting Methods 0.000 claims description 18
- 230000008018 melting Effects 0.000 claims description 18
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 14
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 12
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 7
- 239000007997 Tricine buffer Substances 0.000 claims description 7
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 7
- 235000011056 potassium acetate Nutrition 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- ZLMJMSJWJFRBEC-LZFNBGRKSA-N Potassium-45 Chemical compound [45K] ZLMJMSJWJFRBEC-LZFNBGRKSA-N 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 description 89
- 108020004707 nucleic acids Proteins 0.000 description 89
- 150000007523 nucleic acids Chemical class 0.000 description 87
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 29
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 29
- 238000001514 detection method Methods 0.000 description 25
- 238000003752 polymerase chain reaction Methods 0.000 description 24
- 239000000975 dye Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 230000035772 mutation Effects 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
- 108700028369 Alleles Proteins 0.000 description 16
- 108010014172 Factor V Proteins 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 230000010076 replication Effects 0.000 description 9
- -1 ribose nucleic acids Chemical class 0.000 description 8
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical group COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 6
- 108010017826 DNA Polymerase I Proteins 0.000 description 5
- 102000004594 DNA Polymerase I Human genes 0.000 description 5
- 229930010555 Inosine Natural products 0.000 description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000007846 asymmetric PCR Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960003786 inosine Drugs 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 150000008300 phosphoramidites Chemical class 0.000 description 5
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 241000589500 Thermus aquaticus Species 0.000 description 4
- 241000589499 Thermus thermophilus Species 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010037497 3'-nucleotidase Proteins 0.000 description 3
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 241000206213 Thermosipho africanus Species 0.000 description 3
- 241000589596 Thermus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000011942 biocatalyst Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 108010068698 spleen exonuclease Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000006488 t-butyl benzyl group Chemical group 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- PNWOYKVCNDZOLS-UHFFFAOYSA-N 6-amino-5-chloro-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Cl PNWOYKVCNDZOLS-UHFFFAOYSA-N 0.000 description 2
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001430197 Mollicutes Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 241000204666 Thermotoga maritima Species 0.000 description 2
- 241000204664 Thermotoga neapolitana Species 0.000 description 2
- 241000589501 Thermus caldophilus Species 0.000 description 2
- 241000589498 Thermus filiformis Species 0.000 description 2
- 241000589497 Thermus sp. Species 0.000 description 2
- 241000193758 [Bacillus] caldotenax Species 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical class C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- DUZISSYVMYNFDT-UHFFFAOYSA-N 2-(6-methoxy-2,4-dioxo-1H-pyrimidin-5-yl)acetic acid Chemical compound COC1=C(C(NC(N1)=O)=O)CC(=O)O DUZISSYVMYNFDT-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- RZEXJHGIEXQMTI-UHFFFAOYSA-N 5-(methoxymethyl)-1h-pyrimidine-2,4-dione Chemical compound COCC1=CNC(=O)NC1=O RZEXJHGIEXQMTI-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- LMNPKIOZMGYQIU-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrimidine-2,4-dione Chemical compound FC(F)(F)C1=CNC(=O)NC1=O LMNPKIOZMGYQIU-UHFFFAOYSA-N 0.000 description 1
- BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 description 1
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
- SVXNJCYYMRMXNM-UHFFFAOYSA-N 5-amino-2h-1,2,4-triazin-3-one Chemical compound NC=1C=NNC(=O)N=1 SVXNJCYYMRMXNM-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- LMEHJKJEPRYEEB-UHFFFAOYSA-N 5-prop-1-ynylpyrimidine Chemical compound CC#CC1=CN=CN=C1 LMEHJKJEPRYEEB-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QFVKLKDEXOWFSL-UHFFFAOYSA-N 6-amino-5-bromo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Br QFVKLKDEXOWFSL-UHFFFAOYSA-N 0.000 description 1
- UFVWJVAMULFOMC-UHFFFAOYSA-N 6-amino-5-iodo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1I UFVWJVAMULFOMC-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000192091 Deinococcus radiodurans Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000042303 SPRING family Human genes 0.000 description 1
- 108091078185 SPRING family Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96408907P | 2007-08-08 | 2007-08-08 | |
| US964089P | 2007-08-08 | ||
| PCT/EP2008/006476 WO2009019008A1 (en) | 2007-08-08 | 2008-08-07 | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5'-3' exonuclease activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2562789T3 true ES2562789T3 (es) | 2016-03-08 |
Family
ID=39942715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08785392.5T Active ES2562789T3 (es) | 2007-08-08 | 2008-08-07 | Supresión de la amplificación usando un oligonucleótido y una polimerasa que carece significativamente de actividad exonucleasa 5'-3' |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8071338B2 (enExample) |
| EP (1) | EP2173910B1 (enExample) |
| JP (1) | JP5524838B2 (enExample) |
| CN (1) | CN101778952B (enExample) |
| CA (1) | CA2693384C (enExample) |
| ES (1) | ES2562789T3 (enExample) |
| WO (1) | WO2009019008A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2547053T3 (es) | 2007-08-01 | 2015-10-01 | Dana Farber Cancer Institute | Enriquecimiento de una secuencia diana |
| US8206929B2 (en) * | 2009-01-07 | 2012-06-26 | Roche Molecular Systems, Inc. | Nucleic acid amplification with allele-specific suppression of sequence variants |
| JP6147502B2 (ja) | 2009-10-27 | 2017-06-14 | スウィフト バイオサイエンシーズ， インコーポレイテッド | ポリヌクレオチドプライマー及びプローブ |
| AU2011224534B2 (en) * | 2010-03-08 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Full COLD-PCR enrichment with reference blocking sequence |
| EP2615171B1 (en) * | 2010-09-10 | 2015-11-04 | LSI Medience Corporation | Method for inhibiting nucleic acid amplification using light and highly sensitive method for selective nucleic acid amplification |
| EP3144396B1 (en) | 2010-10-27 | 2020-01-01 | President and Fellows of Harvard College | Methods of use of toehold hairpin primer |
| JP2014507950A (ja) * | 2011-02-28 | 2014-04-03 | トランスゲノミック，インク． | 混合個体群における標的ｄｎａを配列決定するためのキットおよび方法 |
| EP2691541B1 (en) * | 2011-03-31 | 2017-10-18 | Dana-Farber Cancer Institute, Inc. | Method for enriching in single-stranded mutant sequences from mixture of wild-type and mutant sequences |
| WO2012151328A2 (en) | 2011-05-02 | 2012-11-08 | President And Fellows Of Harvard College | Spatial sequestration of dynamic nucleic acid circuits |
| KR102010601B1 (ko) * | 2011-05-04 | 2019-08-13 | 바이오셉트 인코포레이티드 | 핵산 서열 변이체를 검출하는 방법 |
| US9518292B2 (en) | 2011-05-26 | 2016-12-13 | Brandeis University | Methods for suppression PCR |
| US9617392B2 (en) | 2011-07-10 | 2017-04-11 | President And Fellows Of Harvard College | Compositions and methods for self-assembly of polymers with complementary macroscopic and microscopic scale units |
| LT2756098T (lt) | 2011-09-16 | 2018-09-10 | Lexogen Gmbh | Nukleorūgščių molekulių bibliotekos sudarymo būdas |
| EP2570487A1 (en) | 2011-09-16 | 2013-03-20 | Lexogen GmbH | Nucleic acid transcription method |
| US9260714B2 (en) | 2011-12-02 | 2016-02-16 | Roche Molecular Systems, Inc. | Suppression of non-specific amplification with high-homology oligonucleotides |
| US9133490B2 (en) | 2012-05-16 | 2015-09-15 | Transgenomic, Inc. | Step-up method for COLD-PCR enrichment |
| WO2014177540A1 (en) * | 2013-04-29 | 2014-11-06 | Qiagen Marseille | A method for dna amplification with a blocking oligonucleotide |
| JP2016536013A (ja) * | 2013-10-19 | 2016-11-24 | トローバジーン インコーポレイテッド | 疾患における変異の経時的な検出 |
| KR102343605B1 (ko) * | 2014-05-19 | 2021-12-27 | 윌리엄 마쉬 라이스 유니버시티 | 비대립 유전자-특이적 프라이머 및 대립 유전자-특이적 블로커 올리고뉴클레오티드를 중첩하는 조성물을 사용한 대립 유전자-특이적 증폭 |
| EP3198026B1 (en) | 2014-08-07 | 2019-10-09 | Pharmassist Ltd | Method of determining pik3ca mutational status in a sample |
| US12391985B2 (en) | 2014-08-07 | 2025-08-19 | Pharmassist Ltd | Method of determining PIK3CA mutational status in a sample |
| CN107002141B (zh) * | 2014-09-26 | 2021-11-02 | 詹森药业有限公司 | 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者 |
| US9909169B2 (en) * | 2014-12-17 | 2018-03-06 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression |
| JP5813263B1 (ja) * | 2015-03-31 | 2015-11-17 | 日鉄住金環境株式会社 | 遺伝子変異の検出方法及びそれに用いる蛍光標識オリゴヌクレオチド |
| US9657353B2 (en) | 2015-06-26 | 2017-05-23 | Great Basin Scientific, Inc. | Specific detection of organisms derived from a sample |
| US11414686B2 (en) | 2016-05-06 | 2022-08-16 | William Marsh Rice University | Stoichiometric nucleic acid purification using randomer capture probe libraries |
| WO2017214202A1 (en) * | 2016-06-07 | 2017-12-14 | Cepheid | Thermostable polymerase inhibitor compositions and methods |
| CA3046953A1 (en) | 2016-12-12 | 2018-06-21 | Dana Farber Cancer Institute, Inc. | Compositions and methods for molecular barcoding of dna molecules prior to mutation enrichment and/or mutation detection |
| US11174511B2 (en) | 2017-07-24 | 2021-11-16 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for selecting and amplifying DNA targets in a single reaction mixture |
| WO2019099420A1 (en) * | 2017-11-15 | 2019-05-23 | Yan Wang | A method for detecting multiple dna mutations and copy number variations |
| US12331350B2 (en) | 2018-02-20 | 2025-06-17 | William Marsh Rice University | Systems and methods for allele enrichment using multiplexed blocker displacement amplification |
| JP6947464B2 (ja) | 2018-07-19 | 2021-10-13 | バイオフィデリティ・リミテッド | 改善されたポリヌクレオチド配列検出法 |
| CA3103750A1 (en) * | 2018-12-17 | 2020-06-25 | Illumina Cambridge Limited | Primer oligonucleotide for sequencing |
| GB201919186D0 (en) | 2019-12-23 | 2020-02-05 | Biofidelity Ltd | Simplified polynucleotide sequence detection method |
| JP2024531713A (ja) * | 2021-09-13 | 2024-08-29 | ネクスジェン キャンサー ディテクション エルエルシー | 試料中の標的ポリヌクレオチドを検出するための方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163393C (en) | 1994-11-30 | 2003-04-22 | Colleen Marie Nycz | Amplification and detection of mycobacteria nucleic acids |
| US5801155A (en) * | 1995-04-03 | 1998-09-01 | Epoch Pharmaceuticals, Inc. | Covalently linked oligonucleotide minor grove binder conjugates |
| US5849497A (en) | 1997-04-03 | 1998-12-15 | The Research Foundation Of State University Of New York | Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker |
| FR2779154B1 (fr) | 1998-05-27 | 2002-07-12 | Bio Merieux | Procede d'amplification d'au moins une sequence nucleotidique particuliere et amorces de mise en oeuvre |
| AU780119B2 (en) * | 1999-01-06 | 2005-03-03 | Cornell Research Foundation Inc. | Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing |
| EP1253205A1 (en) | 2001-04-24 | 2002-10-30 | LION Bioscience AG | Method of blocking amplification of selected sequences |
| GB0406863D0 (en) | 2004-03-26 | 2004-04-28 | Qiagen As | Nucleic acid sequencing |
| US7803580B2 (en) | 2004-09-10 | 2010-09-28 | Human Genetic Signatures Pty. Ltd. | Amplification blocker comprising intercalating nucleic acids (INA) containing intercalating pseudonucleotides (IPN) |
-
2008
- 2008-08-05 US US12/186,311 patent/US8071338B2/en not_active Expired - Fee Related
- 2008-08-07 CN CN200880102467.XA patent/CN101778952B/zh not_active Expired - Fee Related
- 2008-08-07 EP EP08785392.5A patent/EP2173910B1/en not_active Not-in-force
- 2008-08-07 JP JP2010519376A patent/JP5524838B2/ja not_active Expired - Fee Related
- 2008-08-07 WO PCT/EP2008/006476 patent/WO2009019008A1/en not_active Ceased
- 2008-08-07 ES ES08785392.5T patent/ES2562789T3/es active Active
- 2008-08-07 CA CA2693384A patent/CA2693384C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2173910B1 (en) | 2015-12-09 |
| US8071338B2 (en) | 2011-12-06 |
| JP5524838B2 (ja) | 2014-06-18 |
| CA2693384C (en) | 2015-04-14 |
| JP2010535480A (ja) | 2010-11-25 |
| CN101778952B (zh) | 2016-05-25 |
| EP2173910A1 (en) | 2010-04-14 |
| CA2693384A1 (en) | 2009-02-12 |
| CN101778952A (zh) | 2010-07-14 |
| HK1146094A1 (zh) | 2011-05-13 |
| US20090053720A1 (en) | 2009-02-26 |
| WO2009019008A1 (en) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2562789T3 (es) | Supresión de la amplificación usando un oligonucleótido y una polimerasa que carece significativamente de actividad exonucleasa 5'-3' | |
| ES2589102T3 (es) | Ensayo cuantitativo de amplificación y fusión multiplex de ácidos nucleicos | |
| ES2530273T3 (es) | Amplificación de ácidos nucleicos específica de alelo | |
| ES2608455T3 (es) | Formato de sondas para detectar diferencias de ácidos nucleicos | |
| ES2634428T3 (es) | Amplificación de ácido nucleico con supresión específica de alelo de variantes de secuencia | |
| ES2384681T3 (es) | Extensión de cebadores correctora | |
| EP1746172B1 (en) | Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids | |
| ES2964624T3 (es) | Detección de secuencias de ácidos nucleicos diana usando diferentes temperaturas de detección | |
| ES2527653T3 (es) | Amplificación específica de alelo usando un cebador con un nucleótido modificado | |
| ES2414286T3 (es) | Detección de ácidos nucleicos | |
| CN101528945A (zh) | 2’-终止子有关的焦磷酸解作用激活的聚合 | |
| AU2022294745B2 (en) | Detection of multiple target nucleic acid using multiple detection temperatures | |
| JP2015536685A (ja) | 対立遺伝子特異的ｐｃｒにおける修飾されたリン酸及び修飾された塩基を有するプライマー | |
| ES2656961T3 (es) | Uso de G-Clamp para mejorar la PCR específica de alelo | |
| ES2886605T3 (es) | Procedimiento genérico para la estabilización de ARN específico | |
| EP1606389B1 (en) | Methods for polynucleotide sequence detection | |
| US20160348158A1 (en) | Format of Probes to Detect Nucleic Acid Differences |